Japan-based Nippon Shinyaku Co., Ltd. has signed an option agreement with Baltimore-based Elixirgen Therapeutics, Inc. granting the right to acquire exclusive worldwide commercialization rights to EXG-7001, a locally administered mRNA therapeutic designed to express full-length human dystrophin protein in DMD patients regardless of their underlying genetic mutation. The asset is preclinical, and Elixirgen is preparing to file an IND in the US.
Under the deal terms, Nippon Shinyaku will fund Elixirgen's development costs during the option period, while Elixirgen retains scientific control and executes the program. Elixirgen will receive an undisclosed upfront payment and is eligible for development and sales-based milestone payments contingent on option exercise. Royalty terms were not disclosed. If Nippon Shinyaku exercises the option following US regulatory approval, its US subsidiary NS Pharma, Inc. will commercialize EXG-7001.
Deal context
EXG-7001 is described by Elixirgen as a full-length dystrophin mRNA therapeutic — mechanistically distinct from all currently approved DMD treatments. Approved exon-skipping antisense oligonucleotides, including Nippon Shinyaku's own viltolarsen (Viltepso), produce shortened, internally deleted dystrophin and collectively cover roughly 30% of DMD patients with amenable mutations. Sarepta Therapeutics' delandistrogene moxeparvovec (Elevidys), the only approved DMD gene therapy, delivers a truncated micro-dystrophin via AAV vector and is mutation-agnostic but has faced significant regulatory and safety headwinds following two pediatric deaths from acute liver failure in 2025 and a subsequent FDA boxed warning. EXG-7001's claimed full-length dystrophin delivery and local administration route, if confirmed in clinical development, would represent a differentiated profile relative to both modalities.
Nippon Shinyaku's IRP team in Cambridge, Massachusetts, facilitated the deal — the same unit that brokered a research alliance with Boston Children's Hospital in July 2025 and a nucleic acid drug collaboration with MiNA Therapeutics in 2024.